Michael Moore, President of Viemed Healthcare, INC. (NASDAQ: VMD), sold a total of 136,802 common shares across multiple transactions conducted between March 18 and March 20, 2026. The aggregate proceeds from those sales amounted to approximately $1.23 million, based on the weighted average prices reported for the trades. At the time the stock was trading at $8.71 and has risen 37% over the past six months.
The individual transactions were reported as follows. On March 18, Moore sold 31,570 shares at an average price of $9.42 per share, with individual sale prices ranging from $9.26 to $9.61. The next day, March 19, he sold 40,232 shares at an average price of $9.21, with prices in that batch spanning $9.04 to $9.38. The final reported sale occurred on March 20, when 65,000 shares were sold at an average price of $8.77, with prices between $8.63 and $9.18.
All of the sales were executed indirectly through Moore Faster LLC. After these transactions, Moore is reported to still indirectly own 1,585,812 shares of Viemed Healthcare and to directly own 189,090 shares.
The insider sales come in the context of Viemed's recently released fourth-quarter 2025 financial results. The company reported earnings per share of $0.14, which exceeded analyst expectations of $0.13. Revenue for the quarter was $76.18 million, which fell short of the $77.6 million analysts had anticipated. The quarterly report thus combined a modest EPS beat with a revenue miss, a mix of outcomes that market participants and analysts are monitoring as they evaluate the company’s near-term prospects.
Separately, InvestingPro analysis flagged Viemed as appearing undervalued at current levels. The platform offers eight additional ProTips for VMD and provides a comprehensive Pro Research Report for this and more than 1,400 other U.S. equities.
For investors considering valuation, a promoted tool referenced in the reporting suggests evaluating VMD with a Fair Value calculator that uses a mix of 17 industry valuation models. That tool is presented as a resource for assessing whether VMD or other stocks might represent bargains based on model outputs.
Contextual note - The combination of the insider selling, the Q4 results that beat on EPS but missed on revenue, and third-party valuation commentary form the factual basis for market attention on Viemed at present. The specific transactions, ownership stakes, earnings and revenue figures, and third-party commentary are as reported above.